PRINCETON, N.J., March 9, 2021 /PRNewswire/ -- Sun Pharmaceutical Industries, Inc. (Sun Pharma), a wholly owned subsidiary of Mumbai-based Sun Pharmaceutical Industries Limited, today announced that the top 10 Medicare Part D plans, which include 91% of eligible U.S. lives, now cover Drizalma Sprinkle™.
NAPERVILLE, Ill., July 08, 2020 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations, announced today that it has submitted for U.S. patent protection, for the first-ever powder for oral liquid formulation of duloxetine hydrochloride. Offering an important delivery alternative for a drug often used for major depressive and generalized anxiety disorder, this represents the fourth of several oral liquid options in neuroscience that the company hopes to commercialize over the next several years via 505(b)(2) applications, in keeping with its pipeline of reformulated, approved therapeutics with no currently available liquid formulation.
Having worked on drugs like Zyprexa and Cymbalta over his 17 years at Eli Lilly, Steven Paul, M.D., could have stayed on until the Big Pharma made him retire. He left in 2010 to “do something a bit more entrepreneurial”—he cofounded a pair of central nervous system-focused biotech companies and stepped up to lead a third.
Sun Pharmaceutical Industries has launched Drizalma sprinkle, used for treatment of various neuro-psychiatric and pain disorders, in the American market, the drug major said on Wednesday.
YaoPharma`s Generic Duloxetine Hydrochloride Receives Approval in US
Qingdao Baheal Pharm`s Generic Duloxetine HydrochlorideReceives Approval in US
CSPC Ouyi Pharm's Generic Duloxetine Hydrochloride Receives Approval in US
Breckenridge Pharm`s Generic Duloxetine Hydrochloride Receives Approval In US
Breckenridge Pharmaceutical, Inc. announced today the supplemental approval for the 40mg strength of Duloxetine Delayed-Release Capsules. The U.S. Food and Drug Administration granted final approval for the Supplemental Abbreviated New Drug Application (sANDA), which is being manufactured and supplied by its vertically integrated parent company, Esteve Pharmaceuticals, S.A. Duloxetine Delayed-release Capsules are AB rated to Cymbalta®, a drug marketed by Eli Lilly, for the treatment of Major Depressive Disorder, Generalized Anxiety Disorder, Diabetic Peripheral Neuropathy and Chronic Musculoskeletal Disorder. According to industry data, the prior 12 month's sales for the 40mg strength were estimated at $25M. Launch plans for this product are underway.
Drug firms LupinBSE 0.35 % and Cadila HealthcareBSE 0.50 % are recalling nearly 1.11 lakh units of Duloxetine delayedrelease capsules and 19,812 bottles of Paroxetine tablets, respectively, from the US market, the US health regulator has said.